Abstract

Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8–5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications.

Details

Title
In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study
Author
Morieri, Mario Luca 1 ; Ronco, Claudio 2 ; Avogaro Angelo 1 ; Farnia Filippo 1 ; Shestakova Marina 3 ; Zaytseva Natalya 3 ; Mokrysheva Natalya 3 ; Akulkina Larisa 4 ; Shepalina Anastasia 4 ; Brovko Michail 4 ; Moiseev Sergey 4 ; Russo, Lucia 1 ; Mazzocut Sara 1 ; Vianello, Andrea 1 ; Cattellan, Anna Maria 1 ; Vedovato Monica 1 ; Fadini, Gian Paolo 1 ; Vettor Roberto 1 ; Fioretto Paola 1   VIAFID ORCID Logo 

 University of Padova, Department of Medicine (DIMED), Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470) 
 University of Padova, Department of Medicine (DIMED), Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy (GRID:grid.488957.f) 
 Endocrinology Research Center, Moscow, Russia (GRID:grid.465364.6) (ISNI:0000 0004 0619 9372) 
 Sechenov First Moscow State Medical University, Tareev Clinic of Internal Diseases, Moscow, Russia (GRID:grid.448878.f) (ISNI:0000 0001 2288 8774) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2635112160
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.